Natixis Advisors LLC Sells 5,933 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Natixis Advisors LLC trimmed its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 16.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 29,327 shares of the company’s stock after selling 5,933 shares during the period. Natixis Advisors LLC’s holdings in Neurocrine Biosciences were worth $3,379,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of NBIX. Ashton Thomas Private Wealth LLC acquired a new position in Neurocrine Biosciences during the 2nd quarter worth approximately $28,000. Innealta Capital LLC acquired a new position in Neurocrine Biosciences during the second quarter worth $30,000. New Covenant Trust Company N.A. bought a new position in Neurocrine Biosciences in the first quarter valued at $32,000. EdgeRock Capital LLC acquired a new stake in Neurocrine Biosciences in the 2nd quarter valued at $35,000. Finally, Blue Trust Inc. lifted its position in Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after buying an additional 220 shares in the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Neurocrine Biosciences Price Performance

NBIX stock opened at $125.65 on Friday. Neurocrine Biosciences, Inc. has a fifty-two week low of $110.52 and a fifty-two week high of $157.98. The stock has a market capitalization of $12.72 billion, a price-to-earnings ratio of 33.69 and a beta of 0.35. The business’s fifty day moving average price is $118.62 and its two-hundred day moving average price is $132.02.

Analysts Set New Price Targets

NBIX has been the subject of several analyst reports. Piper Sandler upgraded Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $131.00 to $159.00 in a report on Thursday, August 29th. Citigroup boosted their price target on Neurocrine Biosciences from $150.00 to $158.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Royal Bank of Canada dropped their price objective on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a research note on Friday, October 4th. Jefferies Financial Group boosted their target price on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a report on Monday, August 19th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research note on Monday, November 11th. Five equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $163.91.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.